TB vaccine development: where are we and why is it so difficult?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25432943.
- Also identified by DOI 10.1136/thoraxjnl-2014-205202 and PMC identifier 4345977.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either 'boost' a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.
Medical subject headings
- Mycobacterium tuberculosis
- Tuberculosis Vaccines
- Tuberculosis, Pulmonary